Spots Global Cancer Trial Database for A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
Official Title: A Multicenter, Open-Label, Noncomparative Phase I Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients With Advanced Cancer
Study ID: NCT00535522
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Indiana University Cancer Center, Indianapolis, Indiana, United States
University of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States
Karmanos Cancer Center, Detroit, Michigan, United States
Contact Details
Name: Medical Monitor
Affiliation: Millennium Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
